Cell:全面总结癌症遗传风险图谱!

2018-04-09 佚名 西安交通大学

恶性肿瘤是一大类复杂的多组学(基因)疾病。现代肿瘤学理论认为,肿瘤的发生、发展是肿瘤患者的内因和外因耦合作用的结果,其内因主要是癌症遗传风险。基于多组学大数据,挖掘癌症遗传风险,不仅是肿瘤研究的前沿领域和热点方向,而且能够广泛应用于肿瘤风险筛查、肿瘤分子预警、肿瘤精准体检和早诊。基于大数据绘制癌症遗传风险图谱是癌症遗传风险图谱研究的热点和难点,风险图谱是临床辅助决策的重要基线之一,也是《关于促进和

恶性肿瘤是一大类复杂的多组学(基因)疾病。现代肿瘤学理论认为,肿瘤的发生、发展是肿瘤患者的内因和外因耦合作用的结果,其内因主要是癌症遗传风险。基于多组学大数据,挖掘癌症遗传风险,不仅是肿瘤研究的前沿领域和热点方向,而且能够广泛应用于肿瘤风险筛查、肿瘤分子预警、肿瘤精准体检和早诊。基于大数据绘制癌症遗传风险图谱是癌症遗传风险图谱研究的热点和难点,风险图谱是临床辅助决策的重要基线之一,也是《关于促进和规范健康医疗大数据应用发展的指导意见》明确的、全面深化健康医疗大数据应用的重点任务中具有重要意义的研究和应用模块。

近日,CELL杂志刊发了迄今为止最全面的癌症遗传风险图谱研究。该研究由西安交大计算机科学与技术系、陕西省医疗健康大数据工程研究中心王嘉寅教授团队与圣路易斯华盛顿大学、哈佛大学-麻省理工学院Broad研究所、贝勒医学院、梅奥临床医学院等13家顶级研究机构历时近三年合作完成。该研究基于33种常见癌症类型、共计1万多名肿瘤患者的多组学大数据,全面应用了目前最优的生物信息学分析和实验手段,优化设计了面向多组学的数据处理流程,累计分析了超过14.6亿个候选基因变异,首次系统性报道了871个罕见易感/疑似易感变异和拷贝数变异,且较大比例地存在与基因表达异常、丧失异质性等体细胞突变的耦合,这为下游研究,特别是遗传变异分类和检测奠定了基础。同时,大数据分析明确展示了不同癌症类型的一些病例具有共同或类似癌症遗传风险的关键证据,这些共性模式及其与体细胞突变的相互作用能够为异癌同治提供临床辅助决策依据。



上述研究成果以《Pathogenic Germline Variants in 10,389 Adult Cancers》为题于4月5日发表于 CELL期刊上。该研究得到国家自然科学基金、西安交大青拔计划、中央直属高校基本科研业务费的支持。

原始出处:

Kuan-lin Huang,et al.Pathogenic Germline Variants in 10,389 Adult Cancers.Cell.Volume 173, Issue 2, p355–370.e14, 5 April 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870548, encodeId=29ff18e0548cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 12:06:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960816, encodeId=c3f9196081624, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 24 13:06:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361929, encodeId=6d571361929d4, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Apr 11 10:06:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304445, encodeId=b58a304445ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Apr 10 10:13:52 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870548, encodeId=29ff18e0548cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 12:06:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960816, encodeId=c3f9196081624, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 24 13:06:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361929, encodeId=6d571361929d4, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Apr 11 10:06:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304445, encodeId=b58a304445ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Apr 10 10:13:52 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
    2018-12-24 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870548, encodeId=29ff18e0548cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 12:06:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960816, encodeId=c3f9196081624, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 24 13:06:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361929, encodeId=6d571361929d4, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Apr 11 10:06:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304445, encodeId=b58a304445ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Apr 10 10:13:52 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870548, encodeId=29ff18e0548cc, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu May 31 12:06:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960816, encodeId=c3f9196081624, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 24 13:06:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361929, encodeId=6d571361929d4, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Apr 11 10:06:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304445, encodeId=b58a304445ca, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Apr 10 10:13:52 CST 2018, time=2018-04-10, status=1, ipAttribution=)]
    2018-04-10 yfjms

    学习

    0

相关资讯

皮肤恶性肿瘤早期易误诊,人工智能能帮上什么忙?

问:皮肤肿瘤危险吗?答:良性肿瘤在增大到一定程度后停止生长,不会危及生命;而恶性肿瘤则可以不断增殖,引起转移,威胁生命,也被称作皮肤癌。医学技术不断进步,但“肿瘤”二字依旧令人不安。皮肤肿瘤是发生在皮肤的细胞增生性疾病,包括良性肿瘤和恶性肿瘤。中日友好医院皮肤科主任崔勇教授介绍说,良性肿瘤在增大到一定程度后停止生长,不会危及生命;而恶性肿瘤则可以不断增殖,引起转移,威胁生命,也被称作皮肤癌。色素痣

94岁老人患恶性肿瘤 救她的竟是整形外科

尽管医学技术日趋发达,但仍有一些病症难以治愈。不仅如此,因为受到技术的制约,一些高龄患者无法得到积极的救治只能采取保守治疗,最终等待他们的结局只会是“备受病痛折磨后离开人世”。近日,一名年94岁高龄的婆婆患有恶性皮肤肿瘤,在被多家医院拒绝后迎来柳暗花明。到底是怎么一回事呢?

瞄准前沿“解锁”难题 上海科技进步一等奖医疗占比两成

来自上海市医疗机构的医务人员不断创新理论、探索技术,为提升群众健康水平贡献智慧。

2018年全国全新癌症报告:每分钟有7人确诊为癌

国家癌症中心公布最新统计数据,囊括8大癌种所有信息。

恶性肿瘤患者应该怎么吃?全新专家共识来帮忙!

近日,我国出台了《恶性肿瘤患者康复期营养管理专家共识》。在收集了大量循证医学证据下,专家提出恶性肿瘤患者康复期应重视营养管理,科学饮食,进行规范的营养治疗,避免康复期饮食误区。

吃啥不必再纠结——中国颁布《恶性肿瘤患者膳食指导》

常言道”三分吃药,七分调养”,而饮食是调养最重要的一环。癌症患者该吃什么?该忌什么?日前,国家卫生计生委颁布了《恶性肿瘤患者膳食指导》的卫生行业标准(标准编号:WS/T559-2017)。针对癌症患者膳食的问题,给予最权威的回答。近年来癌症发病率的迅速上升,”吃”已经变成一个非常重要的因素,世界卫生组织发布的《肿瘤饮食之南》,就曾强调不当饮食会导致癌症,特别是脂肪和蛋白摄入过多,长期在体内堆积会导